
Alector Investor Relations Material
Latest events

Q4 2024
Alector
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Alector Inc
Access all reports
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company is developing AL001, an antibody that targets delta-like ligand 4-Notch to address abnormal signaling triggered by microglia in Alzheimer's disease prevention and slowing in patients with mild cognitive impairment and early-stage Alzheimer's disease; AL101, an anti-TREM2 antibody targeting microglia function that is in Phase IIa clinical trial for the treatment of frontotemporal dementia; AL003, an anti-LINGO monoclonal antibody targeting oligodendrocyte precursor cells for myelination; and AL002 and AL004 for preventing or slowing disease progression in Parkinson's disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Key slides for Alector Inc


Status Update
Alector Inc


Status Update
Alector Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ALEC
Country
🇺🇸 United States